Last week, the price of nickel in London declined by more than 8% while the price of the metal over in Shanghai plunged to nine-month lows after an important deal by Tsingshan Holding, a Chinese firm, relieved concerns of supply shortages of battery-grade nickel.
Expectations of a surge in demand from the electric vehicle sector had led to the benchmark prices for the metal trading at six-year highs with many expecting a shortage of the metal as a result.
Earlier in February, Tesla CEO Elon Musk had stated that his company’s top concern was a steady supply of nickel. Prior to this statement, Musk had called for miners to produce more nickel amid concerns that the supply of this battery metal would experience a deficit by 2023.
As a result of the activity, the London Metal Exchange’s three-month nickel price dropped to $15,945/ton, which is roughly 8.5%. This marks its largest intraday loss since December 2016.
In addition, Norilsk Nickel recently announced that it expects to resolve issues with flooding at its Taimyrsky and Oktyabrsky mines in the coming week.
Over on the Shanghai Futures Exchange, the most-traded nickel contract of June closed at 130,510 yuan/ ton, which was 6% lower. The figure, equivalent to $20,180.61, was the exchange’s largest intraday nickel loss since May of last year.
The top stainless steel producer in the world Tsingshan Holding Group Co. is set to begin supplying nickel matte to battery material producers in China. The company is planning to expand its nickel investments in Indonesia, which is the largest producer of nickel in the world. Matte can be processed into battery-grade chemicals and is an intermediate product manufactured from concentrate.
Huatai Futures said in a statement that the mass production of nickel matte by Tsingshan Holding set off a supply side reform. Huatai noted that this action broke nickel sulphate’s supply bottleneck, adding that there was limited room for the price of nickel to increase. In addition, Mysteel analyst Celia Wang revealed to Bloomberg that the producers of nickel-pig-iron could now manufacture nickel matte by slightly modifying its manufacturing process. This, she said, would considerably alleviate concerns of a shortage of materials needed for batteries.
The decline in the price of nickel triggered a drop in share prices. In China, Ganfeng Lithium Co. dropped by 9.7% and Zhejiang Huayou Cobalt Co. declined by 10%, while in Sydney, IGO Ltd. slumped by nearly 8% and Nickel Mines Ltd. dropped by 10%.
The Tsingshan deal has allayed the supply jitters in the nickel market in much the same way as the exploratory work being done by Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) at its Kilgore Project in Idaho has impacted the expected surge in demand for gold. EXN anticipates extracting gold for years to come at this site.
NOTE TO INVESTORS: The latest news and updates relating to Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) are available in the company’s newsroom at https://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2), a silver and base metals producer with operations in Mexico and precious metal exploration projects in Mexico, Idaho and Germany, recently announced a new discovery. High-grade silver mineralization was found at the fourth target drilled at EXN’s Silver City project — Grauer Wolf. A recent article discussing this reads, “According to the announcement, the discovery is located on a geological site with little historical mining and adds a fourth priority area for follow-up in the 2021 drilling program at Silver City. With eight holes still outstanding, there is strong potential for additional discoveries in parallel strikes. The company is in the process of planning and preparing for more extensive drilling for its Bräunsdorf, Reichenbach, Peter Vein and now Grauer Wolf projects.”
Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.
NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at http://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
Local activists from Decriminalize Spokane recently filed an initiative that, if approved, may make Spokane the latest city to decriminalize hallucinogenic mushrooms in the United States.
The measure would prohibit officials from using the city’s resources or funds to enforce laws that impose criminal penalties for the distribution, growing, transportation, possession or use of psilocybin mushrooms. This is in addition to making the distribution, growing and personal possession of psilocybin for individuals aged 21 and over among the lowest enforcement priorities of law enforcement.
Decriminalize Spokane plans to qualify the measure for the city’s ballot. The initiative includes terms forbidding the display or use of psilocybin mushrooms in public spaces as well as a section that directs attention to the scientific research conducted on psilocybin’s therapeutic potential and any low health risks that the psychedelic fungi might pose.
The proposal states that psilocybin can be used to effectively treat trauma, addiction, cluster headaches and depression as well as decrease prison recidivism and reduce end-of-life anxiety for terminal cancer and hospice patients.
The proposal was presented to the City Council earlier in February, with legislators being provided with the option of passing the bill themselves, approving the petition and allowing the voters to vote on it, or declining it and suggesting an alternative.
Legislators decided not to act on the measure, which left the task up to the city officials to make sure the proposal’s language is in accordance with the law before clearing it for signature collection. If activists are successful in gathering enough signatures from registered voters, the proposal could be presented to voters by November 2021. The activists require 3,477 signatures in order for the measure to qualify for the ballot.
Chief petitioner Mason Lord stated in an interview that the measure focused mainly on safety and highlighted the fact that some legal substances, such as alcohol, were considerably more dangerous.
An objective look at the developments in the psychedelics field shows that the movements to legalize or at least decriminalize psychedelics have a basis in science. For example, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) has four candidate psychedelic drug formulations in various stages of development, and all these drugs have potential to revolutionize how mental health conditions are treated.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Brain Scientific (OTCQB: BRSF) is featured in a broadcast released from NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The new audio press release focuses on the 510(k) clearance the U.S. Food and Drug Administration (“FDA”) has given to Brain Scientific’s next-generation NeuroCap(TM) device. The NeuroCap is an advanced clectroencephalogram (“EEG”) electrode array that obtains rapid EEGs in a variety of settings, from routine clinical and research settings to point of contact, where recording of STAT EEGs is needed. BRSF’s proprietary NeuroCap is a disposable, pre-gelled EEG headset with 22 electrodes and 19 active EEG channels. The device can be applied in five minutes and eliminates the time-consuming tasks of head measurement and electrode placement. “We are constantly working on new products for the EEG market,” said Brain Scientific marketing director Irina Nazarova in the press release. “In the new version of NeuroCap, we added Velcro strips for better adhesion. We also expanded the size range by adding an extra small size. And now this device is designed for broader use — in addition to intensive care units and ERs.”
Brain Scientific is a commercial-stage, health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. For more information about this company, please visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
NexTech AR Solutions Corp. (CSE: NTAR) (OTCQB: NEXCF) Joins the Interactive Advertising Bureau’s AR Board; Launches AR-Capable Ad Network
NexTech AR Solutions Corp. recently announced it had joined the Interactive Advertising Bureau’s AR board
This announcement comes at a time when NexTech has been focusing on AR advertising, as seen through the recent launch of its in-house ad network that is similar to Amazon’s and Walmart’s advertisement networks
NexTech, through its Ad Network, will curate ads for each event based on the theme and will be a marketplace where marketers and advertisers meet their target audiences
With the company projecting that its revenues will increase in 2021, the fact that the Ad Network has already begun generating ROI means that it is bound to contribute to this revenue growth
Augmented reality (“AR”) has become a real utility. Buoyed by its use in gaming and entertainment in 2019, AR usage has been on an upward trajectory and has now been more broadly adopted in other industries. As a result, a 2020 survey by VR Intelligence revealed that 65% of companies were developing AR solutions for enterprise use, while 37.4% worked on consumer products and software (https://ibn.fm/K2YrX). NexTech AR Solutions (CSE: NTAR) (OTCQB: NEXCF), which falls in the first category, recently launched its Ad Network and announced it had joined the Interactive Advertising Bureau’s (“IAB”) AR board.
IAB is the leading trade association whose mandate is to empower the media and players in the marketing industry to thrive in the digital economy. Its membership comprises over 650 leading media companies, brands and technology firms responsible for selling, delivering and optimizing digital ad marketing campaigns. By joining IAB’s AR board, NexTech will work with industry peers to build industry standards for AR creative formats, performance benchmarking, measurement standards and privacy considerations.
The membership came as NexTech launched its Ad Network, a private marketplace integrated into its hybrid and virtual experience platform that enables marketers and advertisers to meet their target audience more easily than before. Notably, the hybrid and virtual experience platform, launched in 2020, is one of NexTech’s four digital experience platforms, the others being AR Experiences, AR e-commerce and advertising, Hybrid and Virtual Events and Augmented Learning. These four platforms fall into the company’s four business segments, namely AR, e-commerce, virtual events, and 3D/AR advertising.
The hybrid and virtual experience platform targets clients who need stunning virtual meetings, conferences, trade shows and AR experiences. Besides facilitating virtual events, the platform displays targeted ads, thereby promoting engagements and learning opportunities and ensuring advertisers and attendees interact. “Trade shows, consumer expos and professional conferences are the future of targeted, impactful advertising and offer incredibly cost-effective investment to brands,” Hareesh Achi, President of Advertising at NexTech AR, commented (https://ibn.fm/X8IJq).
NexTech curates the ads for each event and subsequently integrates them within the event platform for viewing by attendees. The result is a seamless experience for the event organizers, event sponsors and attendees. For instance, NTAR could display targeted ads from Colgate if it were running a dental convention on its virtual events platform.
“Our strategy,” Evan Gappelberg, NexTech CEO, explained (https://ibn.fm/Sk37B), “is to take our augmented reality tech stack and evolve them into our virtual and hybrid events platform by first building advertising tools for ourselves but then building a self-serve ad tool for everyone and by providing a distribution channel to a captive audience on our platform.” He continued, “With today’s announcement of the successful market launch of our Ad Network, which is capable of 2D, 3D or AR ads, we’ve laid a foundation for this to happen.”
Gappelberg likened NexTech’s approach to its Ad Network to Amazon’s (https://ibn.fm/XtfTP). “When you think of our Ad Network, it’s something that we’re integrating into our own platforms. It’s a very big deal. It’s exactly what Amazon is doing with their ad network, and Amazon generated $8 billion a quarter with their ad network,” he said in a presentation to investors.
AR advertising holds many advantages for the advertisers as it increases engagements by 20% and conversion rates by between 90% and 200% (https://ibn.fm/fnTV5). By integrating this form of advertising into its platform, NexTech ensures that advertisers experience additional benefits as well. For instance, the platform provides a closed-loop attribution and a clean line of sight into high purchasing power and decision-making individuals. This makes tracking high ROI easy.
Hailed as a powerful in-house advertising network for advertisers, brands and sponsors, Ad Network has already begun generating significant ROI for NexTech and is bound to contribute to the forecasted revenue increase. According to Gappelberg, the company’s revenue is projected to increase from $20 million in 2020 to between $50 and $60 million in 2021.
For more information, visit the company’s website at www.NextechAR.com.
NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
iClick Interactive (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, has announced it will release its unaudited financial report later this month. The company will report Q4 and FY2020 financial numbers on Thursday, March 25, 2021. The company will release the numbers before the U.S. market opens and then will hold a conference call at 8 a.m. ET that same day to discuss the financial report. iClick founder CEO Jian “T.J.” Tang and CFO Terence Li will host the conference call. Interested parties around the world can call in to participate in the call. Numbers to call in are 1-888-346-8982 for the United States; 852-800-905945 for Hong Kong; 86-4001-201203 for China, and 1-412-902-4272 for all other international callers. The live call will also be available on iClick’s website. In addition, an archived webcast of the call, including earnings numbers and slides from the presentation will be available on the company website.
iClick Interactive is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, the company’s proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in 10 locations worldwide including Asia and Europe. For more information about the company, please visit www.iClick.com.
NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK
About ChineseWire
ChineseWire (CW) is a specialized communications platform focused on promising China-based companies that are listed in North America. As one of 40+ brands within the InvestorBrandNetwork (“IBN”), CW provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution to IBN’s millions of social media followers; and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, CW is uniquely positioned to best serve private and public Chinese companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CW brings its clients unparalleled visibility, recognition and brand awareness. CW is where news, content and information converge.
Please see full terms of use and disclaimers on the ChineseWire website applicable to all content provided by CW, wherever published or re-published: https://www.ChineseWire.com/Disclaimer
VANCOUVER, British Columbia, March 11, 2021 — Siyata Mobile Inc. (Nasdaq: SYTA , SYTAW ), a leading global developer and provider of cellular communications solutions for enterprise customers, announces that V.P. of Corporate Development Daniel Kim will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.
Investors can view Mr. Kim’s general corporate presentation once they register for the conference here , and an archived replay of the presentation will be available via the conference website. Investors can also request a 1×1 meeting with Mr. Kim to be arranged following the conclusion of the conference.
About Siyata
Siyata Mobile Inc. is a Business-to-Business (B2B) global vendor of next generation Push-To-Talk over Cellular (PoC) devices and cellular booster systems. Its portfolio of in-vehicle and rugged smartphones enable first responders and enterprise workers to instantly communicate, over a nationwide cellular network of choice, to improve communication, increase situational awareness and save lives.
Its portfolio of enterprise cellular booster systems enables first responders and enterprise workers to amplify its cellular signal in remote areas, inside structural buildings where signals are weak and within vehicles for maximum cellular signal strength possible.
Siyata’s common shares trade on the Nasdaq under the symbol “SYTA” and its warrants under the symbol “SYTAW”.
TORONTO , March 11, 2021 – RIV Capital Inc. (” RIV Capital ” or the ” Company “) (TSX: RIV) (OTC: CNPOF) today announced that PharmHouse Inc.’s (” PharmHouse “) asset purchase agreement (the ” Agreement “) to sell various operating assets, including its facility and certain equipment located at the facility, has been approved by the Ontario Superior Court of Justice pursuant to a Court Order granted today in PharmHouse’s proceedings under the Companies’ Creditors Arrangement Act . The Agreement is subject to certain closing conditions, which the Company anticipates to be satisfied during the next fiscal quarter. The court-ordered stay of proceedings with respect to PharmHouse was also extended to June 30, 2021 .
RIV Capital also announced that it will be making a voluntary payment of $25.0 million to the lenders of PharmHouse’s $90.0 million non-revolving syndicated credit facility (the ” PharmHouse Credit Facility “) relating to the Company’s estimated liability in respect of its guarantee of the PharmHouse Credit Facility (the ” Guarantee Payment “). As noted in the Company’s press release announcing the Agreement which was entered into by PharmHouse on March 3, 2021 , the Company does not anticipate any material changes to the PharmHouse Recoverability Assessment presented in its interim consolidated financial statements for the three and nine months ended December 31, 2020 , available on the Company’s profile on SEDAR. As a result of the Guarantee Payment, the Company’s estimated liability in respect of the PharmHouse Credit Facility will be reduced by $25.0 million . The Company is making the Guarantee Payment prior to March 31, 2021 in order to, among other things, reduce near-term debt servicing costs and for tax planning purposes in connection with the Company’s recent disposition of certain assets to Canopy Growth Corporation, which resulted in a significant capital gain for the Company.
About RIV Capital
RIV Capital is an investment and acquisition company specializing in cannabis with a portfolio of 13 companies across various segments of the cannabis value chain. We believe that bringing together people, capital, and ideas raises the potential of the entire cannabis industry. By leveraging our industry insights, in-house expertise, and thesis-driven approach to investing, we aim to provide shareholders with exposure to specialized and disruptive cannabis companies.
Forward-Looking Statements
This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding the Company’s expectation that the transaction contemplated pursuant to the Agreement will close in the next fiscal quarter; the Company’s estimation with respect to changes to the PharmHouse recoverability assessment; the Company’s estimated liability with respect to the PharmHouse Credit Facility, and the Company’s expectations for other economic, business, and/or competitive factors.
Investors are cautioned that forward-looking information is not based on historical fact but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Our actual financial position and results of operations may differ materially from management’s current expectations.
Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the possibility that the conditions contained in the Agreement will not be satisfied; that the transactions contemplated pursuant to the Agreement will not be completed on or before June 30, 2021 ; that the Company’s liability with regards to the PharmHouse credit facility will materially differ from current expectations; credit, liquidity and additional financing risks for the Company and its investees; litigation risks; stock market volatility; regulatory and licensing risks; cannabis pricing risks; changes in cannabis industry growth and trends; changes in the business activities, focus and plans of the Company and its investees and the timing associated therewith; the Company’s actual financial results and ability to manage its cash resources; changes in general economic, business and political conditions, including challenging global financial conditions and the impact of the novel coronavirus pandemic; competition risks; potential conflicts of interest; the regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; changes in the Company’s relationship with its investees; changes in applicable laws; compliance with extensive government regulation, including the Company’s interpretation of such regulation; changes in the global sentiment towards, and public opinion of, the cannabis industry; reliance on material contracts; risk of default by investees; divestiture risks; and the risk factors set out in the Company’s annual information form for the year ended March 31, 2020 and the Company’s management information circular, filed with the Canadian securities regulators and available on the Company’s profile on SEDAR at www.sedar.com .
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although the Company has attempted to identify important risks, uncertainties and factors that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.
Thursday, March 11th, 2021UncategorizedComments Off on $CNPOF Court Approves Pharmhouse’s Asset Purchase Agreement
Cannabis businesses have had a complicated relationship with banking institutions for quite a while. Although most states allow cannabis in some form, federal law still classifies the plant as a controlled substance, and this difference in legislation has made financial dealings difficult for the cannabis businesses. Most of them have trouble finding financial institutions that are willing to transact with them, let alone offer them loan and financing services.
However, federal data shows that this trend may be coming to an end. For a couple of reasons, the number of banks and credit unions working with cannabis institutions consistently declined for three quarters straight. The coronavirus pandemic was partly to blame, coupled with revised reporting requirements issued by the Financial Crimes Enforcement Network (FinCEN). Based on data from FinCEN’s latest report, this decline seems to be coming to a halt.
Almost 700 banks and credit unions filed reports as of December 31, 2020, stating that they had cannabis businesses as clients. Although these numbers were only a slight increase from the previous quarter, they were significantly lower than the 747 financial institutions reported to be working with cannabis businesses in late 2019. According to FinCEN, which is a bureau of the U.S. Department of Treasury, the number of banks that work with cannabis businesses seems to be leveling off from a decline.
Ever since the 2018 Farm Bill legalized the cultivation and sale of industrial hemp and hemp extracts, FinCEN stopped including hemp-only businesses in quarterly reports. This report was partly to blame for the decline compared to previous figures, which included hemp-only businesses. A report from FinCEN states that the decline coincided with the issuance of guidance it had released together with financial regulators to institutions providing financial services to hemp-only businesses.
The coronavirus pandemic may also be to blame for the decline, with COVID-19 health restrictions forcing many cannabis businesses to close their doors. Additionally, the filing of Suspicious Activity Reports (“SAR”) may have been affected by a reduced workforce at financial institutions. FinCEN guidance requires credit unions and banks to submit SARs if they provide financial services to cannabis businesses. Since the Obama administration issued the guidance in 2014, the number of companies filing SARs report steadily increased until recently.
Filers taking longer than the 90-day follow on requirement to file a continuing activity report may also be to blame for short-term declines in companies working with cannabis institutions, FinCEN says. Now that that decline has stabilized, there may even be an increase in such financial institutions as the Democrats in charge of both the Senate and the House may soon pass cannabis legislation, whether it’s the Secure and Fair Enforcement (“SAFE”) Banking Act or a bill to federally legalize cannabis.
Speaking of access to banking services, lots of companies are doing work that makes them deserving of support and access to banking services so they can continue to do what they do best. An example is XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which is in the advanced stages of bringing to market several cannabis-based drug formulations, including a THC sublingual and oral strip targeting nausea and anorexia.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://cnw.fm/XPHYF
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
Thursday, March 11th, 2021UncategorizedComments Off on $XPHYF 420 with CNW – Federal Data Indicates Decline in Banks Working with Marijuana Firms Is Ending
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder (“MDD”), does not involve direct activation of GABA-A receptors. This is in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons, which in turn regulate limbic amygdala neurons that release excitatory neurotransmitters producing rapid-onset antidepressant effects. “These preclinical data suggest that PH10’s mechanism of action does not work through GABA-A receptors, unlike many other neurosteroids, suggesting it may not have benzodiazepine-like side effects, such as sedation and cognitive impairment, or abuse liability,” said VistaGen’s Chief Medical Officer Mark Smith, MD, PhD. “Using in vitro patch clamp electrophysiology, PH10 had no agonist or antagonist effects on GABA receptors. While PH10 may regulate endogenous GABA circuits in the brain, it does not appear to directly bind to or modulate GABA receptors at concentrations of less than 10 micromolar, which differentiates its mechanism of action from that of benzodiazepines.”
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Thursday, March 11th, 2021UncategorizedComments Off on $VTGN Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines
IAEA report notes that an adequate supply of uranium will be vital as nuclear power continues to provide an important source of the world’s carbon-free energy
“Undiscovered resources must be converted to discoveries, which must then be developed in a timely matter,” report concludes
UEC is focused on expanding uranium production while developing a pipeline of low-cost resources for major ongoing growth
A recent analysis of the world’s uranium supply by the International Atomic Energy Agency (“IAEA”) states that nuclear power will be a primary source of energy for the world in the coming years — assuming an adequate supply of uranium can be maintained (https://ibn.fm/ra0Vo). That report is great news for Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the country’s largest historical uranium exploration and development databases. UEC leverages this invaluable data to target and acquire properties that have been subject to exploration and development by senior energy firms in the past and that are ideally positioned to become major supplies of uranium in the coming years.
“Nuclear power is expected to be an important part of the worldwide energy mix at least through the next 50 years and by most projections well beyond,” the IAEA study reported. “That is, of course, provided an adequate supply of uranium is available to sustain the nominal growth rate for nuclear power of 1 to 3% per year that is projected by many analysts. The importance that a reliable supply will have on the future of nuclear power led the IAEA to undertake a study of uranium supply-demand relationships through 2050.”
The detailed report evaluates the adequacy of the world’s uranium supply to meet demand. The paper analyzes the supply of uranium given different levels of demand, ultimately concluding that “by 2025, primary supply sources are expected to cover 94% of requirements, and the role of Market-based Production is projected to grow from satisfying 45% of requirements in 2000 to 86% in 2025. Known resources are adequate to cover about 96% of Market-based Production requirements in the middle demand case. However, because of resource distribution and production capacity limitations, not all resources will have been depleted by 2050, leaving a cumulative deficit between production and requirements of nearly 850 000 t U. This deficit expands 3.5-fold in the high demand case. Even with the addition of undiscovered EAR-II, there will still be a deficit between production and Market-based Production requirements of about 307 000 t U in the middle demand case.
“The challenge for the uranium production industry will be to discover large, relatively low-cost deposits to fill the projected deficits,” the study concludes. “Plentiful secondary supply has depressed uranium market prices, which in turn has diminished incentive to undertake the exploration programmes needed to offset these deficits. . . . There is not a true shortage of potential resources. However, these undiscovered resources must be converted to discoveries, which must then be developed in a timely manner to ensure that their resources can be fully utilized to offset the projected deficits.”
UEC is focused on doing just that. The company’s mission — to expand uranium production using low-cost in-situ recovery (“ISR”) while developing a pipeline of resources for major ongoing growth — dovetails perfectly with the report from the IAEA noting the need for promising projects to be fully developed. The U.S. Geological Survey recently reported to the International Atomic Energy Agency that South Texas represents one of the world’s most prospective regions for new uranium discovery and development. Uranium Energy Corp has a strong presence in South Texas with the infrastructure in place to capitalize on the region for further exploration, development and production.
UEC discovered the Burke Hollow project in South Texas, and in a recent press release, their vice president of Resource Development stated, “…the extensive, lightly-explored trend extensions and remaining undrilled areas of the project have the potential to be the largest Goliad Formation deposit discovered to date in the South Texas Uranium Belt.” Uranium Energy Corp has the largest resource base of fully permitted projects in Texas and Wyoming of any U.S.-based producer. The company is well positioned to supply the U.S. strategic Uranium Reserve as well as utility demand. UEC also has additional U.S. projects in their pipeline in New Mexico, Arizona, Colorado, and other projects in Canada and Paraguay. UEC is committed to providing low-cost, environmentally friendly uranium for the safe, highly reliable carbon-free energy that nuclear power provides.
NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
PlantX Life (CSE: VEGA ) (Frankfurt: WNT1) (OTCQB: PLTXF), a multifaceted marketplace providing consumers all things plant based, has announced that its founder, Sean Dollinger, will be presenting at the Q1 Virtual Investor Summit. The three-day summit is slated for March 23–25, 2021. Dollinger’s presentation will begin at 11:30 a.m. ET on March 24th and will include compelling information about PlantX Life. Formerly MicroCap Conference, the Investor Summit has gained a reputation as an exclusive, independent conference that connects small cap and microcap companies with qualified investors. This year’s premier event will take place virtually and will feature 100 companies that will be connecting with more than 300 institutional and retail investors. Since the company’s launch in February last year, PlantX Life has focused on offering various services available through its comprehensive online platform, which features more than 5,000 items across diverse product categories. In addition, PlantX has partnered with renowned chefs and nutritionists to provide a tempting array of unique and premade meals delivered to consumers’ homes.
The PlantX platform aims to serve as the digital face of the plant-based community with its one-stop-shop for everything plant-based. The company’s easy-to-use e-commerce shopping experience features plant-based grocery items; meal delivery with recipes created by well-known plant-based chefs throughout the world; a plant shop; weekly easy-to-follow plant-based recipes; partnerships with restaurants, nutritionists, chefs and brands; a forum offering online connection with a community of like-minded individuals; and podcasts, blog articles and an insightful newsletter to research plant-based lifestyle options. Since first launching in February 2020, PlantX Life has offered various services available through its comprehensive platform. This online marketplace features more than 5,000 items across diverse product categories. In addition, PlantX has collaborated with renowned chefs and nutritionists to provide various unique and premade meals delivered directly to consumers’ homes. Headquartered in Vancouver, British Columbia, PlantX’s mission is to spearhead the plant-based movement, celebrate and promote health and well-being, raise plant-based awareness in a hyper-palatable world, connect with the global consumer and forge a welcoming plant-based community. For more information about this company, please visit www.PlantX.com and www.PlantX.ca.
NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at http://ibn.fm/PLTXF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Net Element (NASDAQ: NETE) is in the process of transforming its business model to become a pure-play electric vehicle (“EV”) manufacturer through a pending merger with privately-held Mullen Technologies Inc. Mullen today announced that it has executed a purchase and sales agreement (“PSA”) and opened escrow to purchase an EV manufacturing facility in Tunica, Mississippi. The turn-key facility affords Mullen the opportunity to innovate its manufacturing processes with the availability to assemble vehicles now and optimize product design with simultaneous engineering efforts. Under Mullen ownership, the facility will operate as Mullen’s Advanced Manufacturing Engineering Center (“AMEC”) and Proving Grounds. “Our goal is to sustain 100% of our manufacturing processes in the U.S. and by U.S. workers,” said David Michery, CEO and chairman of Mullen Technologies. “With the establishment of AMEC in Tunica, we are among the very few EV companies that have a manufacturing presence in the U.S.”
Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the U.S. and selected emerging markets. On Aug. 5, 2020, Net Element announced the execution of a definitive agreement to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company in a stock-for-stock reverse merger in which Mullen’s stockholders will receive a majority of the outstanding stock in the post-merger company (the “contemplated merger”). That contemplated merger is subject to customary closing conditions, regulatory approvals and shareholder approval for both companies. For additional information, visitwww.NetElement.com.
NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
BRSF signed MOU with leading provider of digital therapeutics for mental health sector to use data, AI to advance work in mental health disorders
Company will provide proprietary NeuroCap, NeuroEEG devices to collect, transfer data from patients
Collaboration could expand into a number of clinical and commercial applications
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company developing products related to the brain including neurology, AI and machine learning, has signed a memorandum of understanding (“MoU”) with Ehave Inc. (OTC: EHVVF), a provider of digital therapeutics for the mental health sector (https://ibn.fm/ktiLG). The two companies aim to collaborate by using data and AI to correlate biomarkers to identify chronic pain, depression (major and persistent), PTSD, bipolar disorder, general anxiety, ADHD and schizophrenia.
Brain Scientific and Ehave will team up to leverage graph-based AI and linked data protocols to develop neural net algorithms. These algorithms could be used to upload already trained neuronet into a specialized chip that Brain Scientific develops into a temporary e-tattoo or electrodes connected to the micro EEG positioned behind a patient’s ear. The brain e-tattoo is the BRSF’s new AI-powered, graphene-based solution that can process the signals from the sensors and wirelessly transfers data to a cloud application (https://ibn.fm/BH9nV).
Under the MOU, Brain Scientific would provide its proprietary data signal acquisition devices, NeuroCap(TM) and NeuroEEG(TM), for the Ehave platform. Ehave would integrate the devices to collect data from patients in real time and transfer that data into a cloud.
NeuroCap is a patented, disposable EEG headset with 22 pre-gelled electrodes that anyone can set up in five minutes or less to record a patient’s brain activity. The cap is compatible with third-party amplifiers and the device also works with NeuroEEG, a proprietary portable, wireless, 16-channel amplifier that can easily be deployed across a broad spectrum of settings also requires minimal training. The devices allow for raw EEG data to be instantly transferred to a cloud, which enables remote access and interpretation by neurologists. These low-cost, portable and wireless devices provide the same quality of signal as conventional EEG devices and could be employed both in clinical and commercial settings.
For example, one possible aspect of the collaboration could involve Ehave deploying NeuroCap and NeuroEEG in clinical settings with its partner healthcare providers such as psychiatrists, psychologists, psychotherapists and general practitioners. This would allow Ehave to collect the data representing electrophysiological changes in the brain before, during and after psychedelic drug administration.
The MOU may also potentially lead to establishing or partnering with a lab that could be equipped with NeuroCap and NeuroEEG devices to conduct market studies to study consumer behavior and psychology in markets and capture data on different brain-related physiological and mental disorders. Likely to begin in Australia, this application could be rolled out in other locations where Ehave has a presence.
The two collaborating companies will jointly own all data from any transactions arising from the MOU. Ehave will cover the testing and certification cost for products developed under the agreement and will receive full intellectual property rights, including the right to sell and distribute any such products, on a 50/50 split basis after all expenses, including research and development.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Vancouver, B.C., Canada –– Nextech AR Solutions (“Nextech” or the “Company”) (OTCQB: NEXCF) (NEO: NTAR.NE) (CSE: NTAR) (FSE: N29), a diversified leading provider of virtual and augmented reality (AR) experience technologies and services for eCommerce, education, advertising, conferences and events, today announced that The Broad Institute of MIT and Harvard has selected Nextech AR’s Virtual Experience Platform (VXP) to host over a dozen seminars for its work on the Human Cell called ‘The Human Cell Atlas,’ a comprehensive reference maps of all human cells—the fundamental units of life—as a basis for both understanding human health and diagnosing, monitoring, and treating disease.
Evan GappelbergCEO of NexTech comments; “This 3-year contract with the Broad Institute of MIT and Harvard is extremely gratifying and a testament to how our platforms continually are being selected by the best-in-class’.” He continues, “In 2021 we are off to a strong start as we are seeing a continuation in global demand from Fortune 1000 businesses, global organizations, Universities, Associations, nonprofits and well-known brands for our AR technologies and platforms. I believe that we are still just in the first inning of the global digital transformation that began in 2020, being led by 5G, AR, AI, The Internet of Things, blockchain, Cloud, and Edge Computing. The potential of these emerging technologies is truly staggering and I’m humbled that our young company’s technologies are being adopted by large global brands and organizations like the Broad Institute of MIT and Harvard. This 3-year contract and others continues to solidify our place as one of the key technology suppliers of this digital transformation.”
About Broad Institute:
The Broad Institute spans some of Boston’s leading institutions Harvard, MIT, and Harvard-affiliated hospitals and scientific disciplines biology, chemistry, medicine, computer science, and engineering. Today, the Broad community includes more than three thousand scientists, committed to advancing research in areas including infectious disease, cancer, psychiatric research, and cardiovascular disease.
Virtual Experience Platform (VXP): An advanced Augmented Reality and Video Learning Experience Platform for Events, is a SaaS video platform that integrates Interactive Video, Artificial Intelligence and Augmented Reality in one secure platform to allow enterprises the ability to create the world’s most engaging virtual event management and learning experiences. Automated closed captions and translations to over 64 languages. With Nextech’s VXP platform having augmented reality, AI, end-to-end encryption and built in language translation for 64 languages, the company is well positioned to rapidly take market share as the growth accelerates globally.
ARitize(TM) For eCommerce: The company launched its SaaS platform for webAR in eCommerce early in 2019. Nextech has a ‘full funnel’ end-to-end eCommerce solution for the AR industry including its Aritize360 app for 3D product capture, 3D/AR ads, its Aritize white label app it’s ‘Try it On’ technology for online apparel, 3D and 360-degree product views, and ‘one click buy’.
ARitize(TM) 3D/AR Advertising Platform: The ad platform will be the AR industry’s first end-to-end solution whereby the company will leverage its 3D asset creation into 3D/AR ads on it’s owned and operated digital properties..
ARitize(TM) Hollywood Studios: The studio is in development producing immersive content using 360 video, and augmented reality as the primary display platform.
On behalf of the Board of Nextech AR Solutions Corp.
“Evan Gappelberg”
CEO and Director
The NEO has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “will be”, “looking forward” or variations of such words and phrases or statements that certain actions, events or results “will” occur. Forward-looking statements regarding the Company increasing investors awareness are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Nextech to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Nextech will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
The IBN website may contain Third-Party Content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at http://ibn.fm/Disclaimer
Thursday, March 11th, 2021UncategorizedComments Off on $NEXCF Nextech AR Signs 3-Year Platform Deal With The Broad Institute of MIT and Harvard
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, has announced that 3a-diagnostics GmbH (“3a”) has received EN ISO 13485 certification for its rapid point-of-care, SARS-CoV-2 RT-PCR Test System (“Covid-ID Lab”). 3a-diagnostics is XPhyto’s exclusive German diagnostics development partner. In addition the company expects CE-IVD approval for the product this month. These two approvals will allow 3a-diagnostics GmbH to distribute the Covid-ID Lab. The EN ISO approval is the internationally recognized European standard for quality control and management systems in the category of design and manufacture of medical devices, and is accepted through Europe, denoting that the medical device has met and passed relevant European directives and regulations. XPhyto has placed its first order for the Covid-ID Lab, which is designed to be a rapid, accurate and robust COVID-19 test system that offers reduced operating costs and increased convenience and portability. XPhyto has also partnered with 3a to develop a portfolio of oral biosensor screening tests designed to detect bacterial and viral infectious diseases, such as influenza A, group A strep, stomatitis, periimplantitis and periodontitis, as well as additional pandemic-focused biosensors. The two companies anticipate the commercial launch of its first biosensor product sometime in late 2021. “We are pleased to remain on schedule with the launch of Covid-ID Lab and will continue to move forward as efficiently as ever,” said XPhyto CEO and director Hugh Rogers in the press release. “At the same time, our experienced launch team is working hard to bring Covid-ID Lab to market and to establish German and international licensing and distribution partnerships.”
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
Psilocybin is the active psychedelic compound found in many fungus species, including magic mushrooms. On the other hand, phantom limb pain refers to painful sensations that originate…
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
Uranium Energy (NYSE American: UEC) is a Corpus Christi, Texas-based uranium mining and exploration company that controls one of the largest historical uranium exploration and development databases in the United States. The company’s acquired properties are primarily located within the U.S., including Texas, New Mexico, Colorado, Arizona and Wyoming. Through leveraging historical exploration data, UEC has been able to target and acquire properties that have previously been subject to exploration and development by senior energy firms. UEC utilizes low-cost, environmentally friendly in-situ recovery (“ISR”) technology at its fully licensed projects, including Palangana, Burke Hollow, Goliad and Reno Creek. A recent article discussing this reads, “ISR technology involves the circulation of naturally occurring and benign groundwater through a uranium ore body. This natural water (that is unfit for any other use) plus oxygen is pumped into injection wells through the uranium ore body, where the uranium in the host sandstone is oxidized and solubilized. The uranium bearing groundwater continues to flow through the sandstone to the extraction wells, where it is pumped to the surface. This water proceeds to an ion exchange unit (like a big water-softener) for uranium removal, then is pumped back to the wellfield and again re-circulated through the ore body. This recirculation of the same groundwater continues over and over, until the uranium in the sandstone is depleted.”
Uranium Energy is a U.S.-based uranium mining and exploration company. In South Texas, the company’s hub-and-spoke operations are anchored by the fully licensed Hobson Processing Facility, which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay. The company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining. For more information about the company, visit www.UraniumEnergy.com.
NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at http://ibn.fm/UEC
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, today announced that Brock Pierce, the entrepreneur, philanthropist and 2020 presidential candidate, has joined its board of directors. According to the update, Pierce has co-founded, advised and funded over 100 companies to support the creation of new jobs and marketplaces through technological innovation, including many blockchain technologies that have paved the way for cryptocurrency innovations. “Brock Pierce is one of the smartest people and one of the most significant visionaries I have ever met. He has been able to see trends early and has been able to capitalize on those insights. We are honored to have him join our board of directors and are especially honored to have him replace the seat left behind from the passing of Malcolm CasSelle whom we loved, respected and miss daily,” said Christopher Miglino, founder and CEO of SRAX. “Brock shares our vision around the power of the retail investor and the community we have created. He is always at the forefront of new paradigm shifts, and I think the shift in the retail investor is just beginning.”
SRAX is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information about the company, visit www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Companies Look to SRAX Inc. (NASDAQ: SRAX) to Maximize Analytics Insight Capabilities
Data, not time, is now a company’s most valuable asset
Investing in analytics leads to a host of benefits, including higher growth
SRAX’s innovative Sequire technology unlocks stock buyers’ behaviors, trends for issuers of publicly traded companies
Today, businesses need every piece of leverage available in order to compete and maximize corporate efficiencies. Efficiency is underscored by ranking and managing resources—a task that can be a moving target based on trends. Seven years ago, Harvard Business Review made the case that time was a company’s most valuable commodity. In 2017, The Economist contested that data was the world’s – not just a company’s – most valuable asset (https://ibn.fm/d8Asv). The Economist isn’t wrong, as capitalizing on data insights and analytics can save time and, ultimately, make or break a company, according to Forbes’ Insight Team. To that point, digital marketing and data management technology company SRAX (NASDAQ: SRAX) offers a product lineup that, amongst other things, helps companies realize and harness the value of data built into their business.
Consumers are increasingly becoming aware of the value of their data, wanting it to remain private and expecting compensation if it is released. These demands have social media platforms facing backlash from users, as well as growing regulatory scrutiny about marketing used to bait consumers. For its part, SRAX is positioned on the leading edge, building a trusted, opted-in consumer data set that companies can benefit from in multiple ways.
In the Forbes piece titled, “6 Reasons Why Investment in Analytics Is Essential,” the authors lay out a cogent case to not delay making investments in analytics to improve the top and bottom line. Rationale to benefits of comprehensive analytics include building a stronger competitive position, identifying new business opportunities and emerging trends, uncovering ways to reduce expenses, detecting production and service problems sooner; getting a deeper understanding of customers and achieving higher growth.
SRAX offers public companies a comprehensive platform, branded “Sequire,” to see data sets derived from the platform’s more than 3 million active users, consisting of investors and traders from 90+ public companies (https://ibn.fm/wd8Hw). The innovative platform is expanding its analytical prowess, as its accelerating growth means more data, which leads to more users, and so on. Sequire provides its clients valuable insight on behaviors of shareholders and market makers, an easy way to measure ROI on spend with investor relations programs and corporate communications strategies, in addition to combining verified and historical shareholder data to target relevant investors across different channels.
Speaking to the growth and value proposition, Chris Lahiji, founder of LD Micro, the pre-eminent event platform for emerging companies, recently said he sees Sequire as a path to importance akin to an industry business information giant.
“One day executives will rely on Sequire the same way investors rely on Bloomberg,” said Lahiji in a conversation on Sequire’s ability to deliver actionable insights on investor activity (https://ibn.fm/1wU44). That’s a lofty goal, but one not out of reach when considered in context with the benefits laid out by Forbes.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Wordson all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life science and other industries, together with the College of Food, Agricultural and Environmental Sciences (“CFAES”) at Ohio State University, recently announced a strategic agreement for the implementation of PBI’s patented Ultra Shear Technology(TM) (“UST”) platform. PBI is developing three different models of the UST processing instrument, named the BaroShear. All three designs, including a small footprint benchtop model, a medium capacity floor model and an industrial scale, continuous flow model for high capacity, are engineered to perform high shear processing of liquids under controlled temperatures and pressure conditions. Under the collaboration, the models will be set up for demonstration and hands-on use in the world-renowned Ohio State food pilot plant. A recent article discussing this reads, “Together with Ohio State, whose CFAES is a globally recognized leader in the food sciences, PBI has formed a food industry consortium to advance the commercialization of its UST platform through the quality enhancement of beverages, condiments, sauces, and other liquid foods. Consortium members will have access to the UST technology in the Ohio State pilot plant and first rights to license all new UST applications developed through the Consortium.”
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life science and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented, enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) recently acquired, patented technology from BaroFold Inc. (the BaroFold technology) to allow entry into the bio-pharma contract services sector, and (2) recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher-quality, homogenized, extended shelf-life or room-temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
The market sell-off since mid-February could have opened new opportunities for certain penny stocks & certain industries. If you look at some of the niches that took the brunt of this drop, biotech is one of the sectors to give back its 2021 gains.
I took a look at some of the industry benchmark ETFs like iShares Nasdaq Biotechnology Index Fund ( NASDAQ: IBB ) and the SPDR Biotech ETF ( NYSE: XBI ). Both have mirrored this trend. Since reaching highs of around February 9th, the XBI has fallen more than 25%. The IBB reached highs of $174.04 on February 10th but has fallen to lows of $142.47 since then, a drop of 22%.
Despite this as the case, some traders are hunting for potential opportunities like this. The market was red hot at the start of 2021, to this correction has come as a warm welcome for some. In fact, both ETFs have attempted a rebound since pulling back. The last few sessions have seen higher highs, and some sector stocks have mimicked the move.
Is the biotech trade back in motion? We’ll have to see how things work out moving forward. But what we can see is that certain emerging trends in biotech have helped give some stocks a boost recently. With this in mind, some of these could be among the list of hot biotech penny stocks to watch in March.
One of the emerging trends in biotech has been psychedelics and the study of multiple drugs. There’s even been the launch of the first-ever psychedelic ETF, PSYK. While this industry is still very new, and most treatments are still in the early stages, it doesn’t negate that traders are vying for position with breakthrough companies.
PharmaDrug Inc.
PharmaDrug Inc. is a unique player in the space. It focuses on natural medicine, in general. This includes not only psychedelic compounds but also cannabis. The company’s focus right now is on international markets. In psychedelics, PharmaDrug utilizes a two-pronged approach. The first targets markets in The Netherlands by consolidating legal adult-use psychedelic dispensaries or “Smart Shops.”
Secondly, the company looks to use its controlled substance import and distribution license to establish a pharmaceutical psychedelic business. Starting in Amsterdam, PharmaDrug will begin rolling out this model and duplicating it in 5 follow-on cities in the country. The company’s wholly-owned subsidiary Super Smart is the retail psychedelics arm specializing in the sale of psychoactive substances in the Netherlands.
One of the more unique aspects of PharmaDrug’s psychedelic platform is that it’s focusing on the use of N, N-Dimethyltryptamine, better known as DMT. The addition of world-renowned chemist and neuroscientist Dr. Steven A. Barker, Ph.D., could take this research initiative to a whole new level. It’s also one of the lesser-explored niches of the psychedelic arena right now.
Meanwhile, PharmaDrug holds a Schedule 1 Narcotics Distribution License, enabling the import of narcotics into Germany. The company is already importing cannabis from one of the largest medical marijuana companies globally, Bedrocan, allowing the company to sell Bedrocan’s brand in the German market. What’s more, the company has already begun expanding its offerings in Germany beyond Bedrocan. It brought on another line of medical cannabis, allowing PharmaDrug to build upon its sales volumes and expand its pharmacy network.
Seelos Therapeutics
Believe it or not, unlike the cannabis industry early on, psychedelic companies are already listing on major exchanges. There’s also been the first big psychedelic stock IPO when Compass Pathways went public in 2020. In light of this, a handful of main listed companies are exploring this niche. Seelos Therapeutics is one of them. Though it has other treatments in its pipeline, the main point of interest for psychedelic stock traders is the company’s SLS-002 treatment. This is Seelos’ intranasal racemic ketamine for treating acute suicidal ideation and behavior in major depressive disorder patients.
This month the company completed open-label patient enrollment for part 1 of its SLS-002 proof of concept study. Seelos is planning to release key open-label data next quarter. This Part 1 includes a 16-day treatment period followed by a safety follow-up period to day-30. To give you a timeline, the final patient is expected to complete Part 1 of the study on April 1st.
Our first look at the potential efficacy of SLS-002 in depressed and imminently suicidal patients should provide valuable insights in this large unmet need. We look forward to initiating Part 2 of this study and are continuing to identify more trial sites,” said Raj Mehra Ph.D., Chairman, and CEO of Seelos.
This week, analysts at Benchmark raised their price target on SEEL stock. Formerly, the company had a $4 target but boosted that significantly higher to $6.
Healthcare & Biotech Penny Stocks Gain Steam
Aside from the fringes of psychedelics, traditional healthcare and biotech penny stocks have gained ground as well. This includes companies developing novel treatments as well as those designing medical devices.
Milestone Scientific Inc.
Shares of Milestone Scientific rose to fresh, 52-week highs on Wednesday. This now marks a run of over 100% since the beginning of 2021. While the company doesn’t have a novel treatment pipeline, it does develop drug delivery products. In this case, its designs injection products. It also offers a suite of diagnostics solutions as well as pending entry into markets like medical injuries, cosmetic surgery injections, and those which are self-administered.
This month the company began sales of its CompuFlo/CathCheck disposables to a nationally recognized medical university, the Medical University of South Carolina. MUSC Health owns and operates eight hospitals and provides patient care throughout the state of South Carolina.
“This decision by another leading U.S. medical center further illustrates the favorable response to both CathCheck and CompuFlo as we execute on our goal to become the new standard of care in epidural procedures.”
Arjan Haverhals , President of Milestone Scientific
Predictive Oncology Inc.
Shares of POAI stock continued rallying on Wednesday, which continued a 3-day move for the stock after its last pullback. Predictive focuses on artificial intelligence to personalize medicine and drug discovery. This week the company announced its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY ® System for direct-to-drain fluid waste management. According to the company, the new device will see no change to its intended use and will not require a separate 501(k) submission with the Food and Drug Administration.
“Skyline Medical plans to follow shortly with a Generation 3 Plus machine which includes an integrated on board vacuum pump so the facility vacuum supply will not be required or at the least can be augmented if needed,” commented Dr. Carl Schwartz, CEO of Predictive Oncology.
This development came a few weeks after announcing the completion of data generation milestones in its study to build AI-driven models of ovarian cancer. This is being done in collaboration with UPMC-Magee Women Hospital. According to Predictive, these data will drive both its AI-models of ovarian cancer and internal ovarian cancer drug repurposing projects.
Wednesday, March 10th, 2021UncategorizedComments Off on $POAI 4 Hot Penny Stocks To Watch If Biotech Is Your Focus In March 2021
FN Media Group Presents Microsmallcap.com Market Commentary
New York, NY – March 10, 2021 – With the plant-based lifestyle continuing to make waves and sustaining a mainstream presence the past few years, companies are seeking out innovative ways for people to maintain their plant-based diets. As such, companies are introducing products they describe as more “clean-based”. Plant-based ingredients can be found in an array of products, from protein shakes to baby formulas, and companies like Else Nutrition Holdings Inc. (TSXV:BABY) (OTCQX:BABYF) , PlantX Life ( CSE:VEGA) (OTCQB:PLTXF), Beyond Meat (NASDAQ:BYND), Kraft Heinz Co . (NASDAQ:KHC), and Burcon Nutrascience Corporation (TSX:BU) (OTCQB:BUROF) are all working towards bringing forward these new, innovative, cleaner products to market.
Else Nutrition (TSXV:BABY) (OTCQX:BABYF) announced a new addition to its plant-based family, a patent-pending clean processing of ingredients for its infant formula . With Else Nutrition already known for its innovative idea of a non-dairy-based infant formula, the new process was created to further ensure the health, nutrition, and safety of the baby formula for all babies, toddlers, children, and their practicing plant-based families. The plant-based formula contains all the required amino acids and macronutrients. Else Nutrition is also committed to safely manufacturing its products while it improves the way it sources its ingredients . The main purpose of the company’s actions is to enhance environmental and public health now and into the future.
“We’re leading a clean revolution, disrupting the baby food industry by setting a new standard in quality, transparency and sustainability,” explained Hamutal Yitzhak, CEO of Else Nutrition . “This latest development brings us even closer to bringing clean label, plant-based, minimally processed infant formula to wanting parents worldwide.”
The core ingredients of Else Nutrition’s baby formula contain almonds, tapioca, and buckwheat. When producing the baby formula, the ingredients go through a thorough clean and all-natural process that maintains the fiber, vitamins, and phytonutrients. Else Nutrition aims to create the most optimal baby formula that is free of dairy, soy, and corn syrup.
In addition to the expansion of its formula line, Else Nutrition has partnered with PlantX Life (CSE:VEGA) (OTCQB:PLTXF) , which will carry Else’s baby formula on the PlantX US platform.
Else Nutrition CEO Hamutal Yitzhak commented, “we are thrilled to be listed on the PlantX platform. Joining this innovative online platform solely dedicated to plant-based companies aligns perfectly with our mission to bring clean label and sustainable plant-based options for parents to nourish their infants.”
PlantX Life was recently named the digital face of the growing plant-based community . PlantX Life offers approximately 10,000 plant-based products and continues to grow its product line with partnerships and new additions to the company.
The onset of the world health crisis has caused an impact on the global meat industry, which has led a lucrative opportunity for the vegan food market . Beyond Meat (NASDAQ:BYND) has tried to fulfill the gap by producing products that have similar characteristics to animal-based meats, such as taste, texture, and appeal. Beyond Meat has produced items that mirror chicken, pork, and beef for consumers who are plant-based or looking for alternatives to traditional meat products.
The buzz around Kraft Heinz (NASDAQ:KHC) is that it may be looking into potentially producing a vegan cream cheese and entering the plant-based cheese industry. With consumers looking to make better and healthier choices, Kraft Heinz is trying to seek out what customers are looking for by releasing a survey asking about this product need. In the early 2000s, Kraft Heinz introduced a vegetarian burger under its alternate label “Boca”. Kraft Heinz has since reformulated the item in order to tap into the growing industry of plant-based foods.
Burcon Nutrascience (TSX:BU) (OTC:BUROF) , a plant protein company, has also announced its new venture by partnering with Merit Function Foods to produce its latest innovation–Peazazz and Peazac proteins. Together, both companies are aiming to create protein items that offer all the benefits of a plant-based diet by creating alternatives to dairy and meat products, while maintaining a good taste and functionality.
As the plant-based industry continues to grow, this movement is becoming more trendy as time goes on. Else Nutrition is seeking to disrupt the traditional production of baby formulas and its latest innovation offers ingredients and a clean process that question traditional approaches.
DISCLAIMER: Microsmallcap.com (MSC) is the source of the Article and content set forth above. MSC owns StreetSignals.com. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MSC or any company mentioned herein. The commentary, views and opinions expressed in this release by MSC are solely those of MSC and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MSC and FNM for any investment decisions by their readers or subscribers. MSC and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (MSC), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (MSC) has not independently verified or otherwise investigated all such information. None of the Author, MSC, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by MSC, a non-affiliated third party to distribute this release on behalf of Else Nutrition Holdings.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MSC and FNM undertake no obligation to update such statements.
Media Contact:
FN Media Group, LLC
info@financialnews.com
+1(561)325-8757
Wednesday, March 10th, 2021UncategorizedComments Off on $PLTXF Advances in Clean Processing of Ingredients Could Further Invigorate Plant-Based Lifestyle
Unlike conventional gas-powered vehicles that run on an internal combustion engine (“ICE”), electric vehicles (“EVs”) are powered by rechargeable lithium-ion battery packs. EV battery technology is still relatively new, and battery makers, as well as EV firms, are working to develop designs that are cheaper, more energy dense and last longer. However, rechargeable EV batteries will degrade over time and after ten or 20 years, most EV owners have to replace the battery pack.
So where do these used batteries go? They usually still maintain around 70–80% of their original capacity at this point. Although this isn’t enough to power an electric vehicle, it is more than enough capacity for several other applications. Recycling used batteries makes more economic and environmental sense than chucking them in the bin, and being repurposed as power storage solutions has emerged as the most viable reuse option.
Industrial consumers with high-energy storage needs could benefit a great deal from second-hand EV battery packs. These batteries can usually perform less taxing tasks for 7–12 years years after they are removed from an EV. Australian technology developer Relectrify is an early entrant into the used-EV market, repurposing and selling used Nissan Leaf battery units to provide storage for renewable power at farms and factories.
According to Relectrify CEO Valentin Muenzel, Relectrify, this space has a great demand for power storage solutions but has so far seen limited supply. BloombergNEF analyst Yiyi Zhou concurs, stating that although the segment is poised to grow, especially as more EV batteries lose capacity, limited incentives coupled with complex economics have stopped battery storage solutions from taking root. Industrial consumers should have 325 gigawatts of power storage capacity by 2030, she observes.
For instance, Muenzel notes, industrial factories and farms equipped with rooftop solar will need to store the excess power the solar panels generate during the day. One thing that would boost the adoption of used EV batteries for storage solutions among industrial consumers would be lower costs, he says. Relectrify’s products are as much as 50% cheaper than brand-new battery systems, and they offer at least 75% of the battery’s original lifespan.
The Melbourne-based firm technology developer has partnered with companies such as Volkswagen AG and American Electric Power to test its products. Although most of its sales have been in New Zealand and Australia, Relectrify is looking to expand to Europe, the United States and Asia.
The EV space is likely to see the introduction of plenty of innovative products as numerous new players come on board. For instance, payment-as-a-service company Net Element (NASDAQ: NETE) is set to make an entry into the electric vehicle sector once its merger with Mullen Technologies Inc., a manufacturer of fully electric vehicles, is completed.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that its Chief Executive Officer, Doug Drysdale, will be presenting a business and pipeline update at the Stifel GMP Health Care Conference – Health Care Psychedelics: Addressing the Global Mental Health Crisis. Drysdale’s presentation is scheduled to begin at 1:00 p.m. Eastern Time on Thursday, March 11, 2021. The presentation will be webcast live at https://ibn.fm/yLkYT and available for seven days following the event.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at http://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
CNS Pharmaceuticals (NASDAQ: CNSP) CEO John Climaco, in a recent podcast, showed his excitement at news that the U.S. Food and Drug Administration (“FDA”) had granted Berubicin investigational new drug (“IND”) status. The IND designation clears the way for the company to start human clinical trials and to ship the experimental drug across state lines to clinical investigators. “This is the biggest news we’ve announced since our IPO back in November 2019,” Climaco said of the significant milestone. “Based on that IND approval, we expect, in the next 90 to 120 days, we will go from zero active clinical trials today to three active clinical trials… We have five employees at this company, so we are a tiny little shop. But we have an absolute powerhouse compound.”
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
An irregular heartbeat, which is scientifically termed as a cardiac arrhythmia, can begin at a moment’s notice before rapidly becoming worse.
A couple of decades ago, in the ‘60s, a physician by the name of L. Julian Haywood found a way to monitor an individual’s heart continuously, watching for a change in its rhythm and then alerting doctors and nurses when an anomaly was found.
Before that, in 1956, Haywood was in year two of his internal medicine residency at the Los Angeles County General Hospital. He had concluded his residency at the Howard University and the University of Virginia before deciding to specialize in cardiology.
However, he was disappointed to learn that the hospital had no cardiology review conferences where students and doctors could talk about any new developments or patients; neither did it have clinical cardiology rounds nor formal teaching in cardiology. This was despite the fact that the hospital’s mortality rate among patients who had heart attacks was 35%.
Despite the many inventions that had been designed over centuries ago to monitor the activity of an individual’s heart, including the capillary electrometer, which was invented in the early 1870s by Gabriel Lippmann, and the string galvanometer, invented by Willem Einthoven in 1893, cardiology was still not considered a specialty when Haywood was concluding his residency at the L.A County General Hospital.
It wasn’t until 1966 that Haywood began a coronary care unit. He also secured funds from the American Heart Association’s L.A. chapter to begin a cardiology nurse training program. With the objective being to reduce the mortality rate of heart attack victims, Haywood began to look for a reliable way that would allow physicians to monitor a patient’s heart and record any anomalies.
Together with his associates, Haywood developed a digital heart monitor prototype in 1969 and began using it in the coronary care unit. This helped significantly reduce the cardiac patients’ mortality rates in the unit.
Decades later in 2018, Haywood published an article that discussed the various factors that led to the significant decline in the heart disease death rate in the county of Los Angeles. In the article, he deduced that the establishment of coronary care units in the ’60s helped bring focus on cardiology, which led to advancements being made in bypass surgery, angioplasty and angiography as well as better medications to control cholesterol and blood pressure.
In addition to this, the success of cardiothoracic surgery and cardiology programs at various institutions encouraged more research in this field to be conducted, which led to various lifesaving inventions such as heart valve replacements and pacemakers.
When talking about heart health, it is almost inevitable that one will think about brain health (due to heart disease increasing the chance of stroke, for example), and lots of companies have brought advances to the neurological sector. A clear example is Brain Scientific Inc. (OTCQB: BRSF), which so far has two devices (NeuroEEG and NeuroCap) that are revolutionizing the EEG market since they are disposable and provide diagnostic results faster.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of nonsystemic, recombinant therapies for gastrointestinal diseases, has announced that its CEO James Sapirstein will present at the virtual Maxim Group Emerging Growth Virtual Conference. The two-day conference is slated for March 17–18, 2021. During the online event, all registered attendees will be able to access Sapirstein’s presentation on demand. The presentation will include an overview of AzurRx BioPharma, including its business and clinical-development programs; Sapirstein will also talk about goals and accomplishments the company is working toward in 2021. Following the presentation, Sapirstein and other members of the AzurRx management team will be available to participate in virtual one-on-one meetings with any interested registered investors as well as pharmaceutical companies attending the event.
AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.
NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at http://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
TEMPE, Ariz., March 09, 2021 — WRAP Technologies, Inc. (NASDAQ: WRAP) (“WRAP” or the “Company”), a global leader in innovative public safety technologies and services, today announced that it will participate in the 4 th Annual D.A. Davidson Consumer Growth Conference being held virtually. Tom Smith, CEO, is presenting at the conference on Thursday, March 11 th at 2:45 pm ET. The fireside chat format will be hosted by D.A. Davidson Managing Director and Senior Analyst Linda Bolton Weiser.
Investors interested in listening to this virtual presentation may reach out to your D.A. Davidson salesperson for details on the event.
About Wrap Technologies
WRAP Technologies (Nasdaq: WRAP) is a global leader in innovating public safety technologies and services that deliver advanced solutions focused on avoiding escalation. The BolaWrap® Remote Restraint device, WRAP’s first product, is a patented, hand-held device that discharges a Kevlar® tether to temporarily restrain from a safe distance. Through many field uses and growing adoption by agencies across the globe, BolaWrap is proving to be an effective tool to safely detain persons without injury. WRAP Reality, the Company’s virtual reality training system, is an immersive training simulator and comprehensive public safety training platform designed to empower first responders with the necessary knowledge to perform in the field. WRAP’s headquarters are located in Tempe, Arizona. For more information, please visit wrap.com .
Trademark Information
BolaWrap and Wrap are trademarks of WRAP Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for countries outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
Contacts
For Investors:
Wrap Technologies, Inc.
Paul M. Manley
VP – Investor Relations
(612) 834-1804 pmanley@wrap.com
Tuesday, March 9th, 2021UncategorizedComments Off on $WRAP to Participate in D.A. Davidson 4th Annual Consumer Growth Virtual Conference
DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial and business update report for the fourth quarter and full year 2020. The company reports significant progress across all aspects of its long-term strategic operating plan, including securing several accounts in the B2B (“B2B”) channel that are generating revenue and enrolling members and completing financing that provides capital to move forward on growth initiatives. In addition, DRIO’s acquisition of Upright allows the company to expand its digital therapeutics offering to include musculoskeletal. Other highlights included DRIO’s agreement to provide its digital therapeutics solution to eligible employees of the subsidiary of a U.S.-based Fortune 500 technology and engineering company and its agreement to provide its exclusive remote patient monitoring (“RPM”) solution to Presbyterian Medical Services, one of the largest integrated healthcare systems in New Mexico. The company also saw key additions made to its commercial management team and advisory board. In addition to releasing the report, Dario will host a simultaneous webcast and conference call to discuss the quarterly report. Interested parties can access the event by calling 877-451-6152 (domestic) and 201-389-0879 (international). A replay of the call can be accessed by dialing 844-512-2921 (domestic) or 412-317-6671 (international) and using the replay passcode 13716928. “The year 2020 was transformational for our company, as we made significant progress across all three pillars of growth: our transformation to a software as a service (SaaS) business model with high margin recurring revenues; our transition to a Business-to-Business-to-Consumer (B2B2C) focused digital therapeutics provider with larger member pools and lower customer acquisition costs; and the ongoing expansion of our product offering to manage multiple chronic conditions,” said Dario CEO Erez Raphael in the press release. “We won multiple contracts during the year that I believe validate our transition to B2B2C and provide a foundation for meaningful growth in 2021. We believe that our successful implementation and penetration of these contracts will contribute to growing revenue throughout 2021. . . . As we enter 2021, we have already launched, and are generating revenue from, all of the contracts that we have previously announced. Early enrollment has been robust and consistent with our expectations. We believe that these customer launches will contribute, along with anticipated additional contracts, to growing revenue in 2021 and beyond.”
DarioHealth Corp. is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
